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ABSTRACT: Combination antiretroviral therapy is the mainstay of HIV treatment, lowering plasma viral levels below detection. However, 
eradication of HIV is a major challenge due to cellular and anatomical viral reservoirs that are often protected from treatment by efflux trans-
porters, such as P-glycoprotein (P-gp) at the blood-brain barrier (BBB). Herein we described a Trojan horse approach to therapeutic evasion 
of P-gp based on a reversibly-linked combination of HIV reverse transcriptase and protease inhibitors. Potent inhibition of P-gp efflux in cells, 
including human brain endothelial cells, was observed with the linked heterodimeric compounds. In vitro regeneration of active monomeric 
drugs was observed in a reducing environment with these dimeric prodrugs, with the superior leaving group promoting more facile release from 
the tether. These release trends were mirrored in the efficacy of the in cyto anti-HIV-1 activity of the Trojan horse heterodimers.  
1. Introduction
HIV treatment has progressed substantially since the first docu-
mented case with combination antiretroviral therapies (cART) suc-
cessfully reducing of plasma viral levels below the detectable limit.1 
Although cART has been a significant advancement in HIV treat-
ment, HIV has not been eradicated due, in part, to viral reservoirs.2-3 
These viral reservoirs exist in a number of cellular and anatomical 
locations, including the central nervous system (CNS), macro-
phages and lymphocytes. Viral accumulation in the brain, for in-
stance, has been proposed to mainly proceed through paracellular or 
transcellular diapedesis.4 While HIV is able to enter the brain 
through these mechanisms, numerous cART treatments do not ac-
cumulate well in the brain due to the physiochemical properties of 
the drugs, the presence of tight junctions, and the high concentration 
of efflux transporters at the blood brain barrier (BBB).5-7 One of the 
well studied efflux transporter, P-glycoprotein (P-gp), resides in the 
apical membrane of brain capillary endothelial cells where it is 
known to efflux many therapies.8-9  
P-gp has many substrates, including various cART drugs targeting
HIV-1 protease (PR), reverse transcriptase (RT), and integrase 
(IN). In vitro and in vivo experiments confirm that RT inhibitor 
drugs, such as abacavir, PR inhibitors, such as nelfinavir and da-
runavir, and IN inhibitor drugs, such as raltegravir, for instance, are 
P-gp substrates.6,10-16 Notably, in P-gp null mice studies, abacavir and
nelfinavir accumulated in the brain at increased levels as compared 
to wild-type mice (20-fold and 36-fold, respectively).10,17 Further,
chemical inhibition of P-gp efflux with a known inhibitor, LY-
335979, was shown to increase the brain accumulation of four differ-
ent PR inhibitors (PI) in-vitro and in-vivo.18  Such studies strongly 
support the hypothesis that P-gp efflux limits the accumulation of 
cART drugs in the brain, leaving viral replication unchecked.  
     An x-ray structure of P-gp has shown a large binding site region 
that can accommodate the binding of two cyclic peptides.19-20 To 
block P-gp efflux, we wished to take advantage of this multiplicity of 
binding sites within the transmembrane domain of P-gp.19-26 In this 
way we envisioned that taking two antiviral agents that are substrates 
of P-gp and combining them into the same molecule with a linker, 
would allow the heterodimeric compounds to occupy the multiple 
binding sites within P-gp, thereby turning 2 two substrates into one 
inhibitor. Dimerizing a P-gp substrate has been demonstrated to be 
an effective means to inhibit P-gp efflux in cells and in situ at the 
BBB.27-36 Using this concept for antiviral substrates, reversibly linked 
homodimeric prodrugs of abacavir demonstrated potent P-gp inhi-
bition with cellular anti-HIV-1 activity.32 This proof of concept study 
paved the way for the current Trojan horse (TH) design (Figure 1), 
a reversible combination therapy in one molecule that also may act 
as a P-gp inhibitor to improve cell accumulation. Specifically, agents 
were designed as an cART prodrug containing the RT inhibitor 
(RTI) abacavir (Aba) and one of two PR inhibitors (PI), nelfinavir 
(NFV) or darunavir (DRV), linked via a disulfide-containing tether. 
Such compounds were designed to inhibit P-gp efflux and, in the re-
ducing environment of an HIV infected cell, release two monomeric 
therapies within the cell. Herein, we discuss the successful synthesis 
and application of two cART heterodimers, Abacavir-S2-Nelfinavir 
(Aba-S2-NFV1) and Abacavir-S2-Darunavir (Aba-S2-DRV8), as P-
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 gp inhibitors and antiviral prodrugs, that highlight the importance of 
the chemical connectivity on their antiviral activity. 
 
Figure 1. (a) Design of Trojan horse (TH) prodrugs containing a 
reverse transcriptase inhibitor (RTI), abacavir (Aba), a protease in-
hibitor (PI) (nelfinavir (NFV) or darunavir (DRV)) and a disulfide-
containing tether. (b) Structures of Abacavir-S2-Nelfinavir-1 (Aba-
S2-NFV1) and Abacavir-S2-Darunavir-8 (Aba-S2-DRV8). 
2. Results and Discussion 
2.1 Design. TH combination cART prodrugs were designed to pro-
vide two functions (1) inhibit P-gp efflux in brain endothelial cells 
and T-cells and (2) in the reducing environment of cells, release the 
monomeric therapies for interaction with target enzymes (Figure 1). 
This was accomplished by conjugating two classes of known FDA 
approved HIV-1 drugs, a RTI (Aba) and PIs (NFV and DRV) con-
nected by ester linkages via a disulfide-containing tether. This tether 
contains a central disulfide moiety that is reduced in the reducing 
environment of the cell. The thiols that are generated can then rear-
range to release the monomeric drugs of interest within the cell. 
Thus, the design creates TH heterodimers that may be useful tools 
in the treatment of cellular and anatomical reservoirs of HIV-1.  
 
Scheme 1. Synthesis of Aba-S2-NFV and Aba-S2-DRV analogs A) 
PyBOP, DMAP, DIEA, DMF, RT 24 hr, 70% yield; B) EDC, 
DMAP, DIEA, CH2Cl2, 4 Å molecular sieves, 0 o C for 2 h, RT for 48 
h;  Aba-S2-NFV1, 62% yield; Aba-S2-NFV18, 3% yield; and (Aba-
S2)2-NFV, 2% yield. Aba-S2-DRV8, 27% yield; (Aba-S2)2-DRV, 21% 
yield. Atom numbering used for NMR analysis of Aba-S2-COOH, 
darunavir and nelfinavir derivatives. 
2.2 Synthesis and characterization of TH dimers Aba-S2-Nelf and 
Aba-S2-Darun. The TH heterodimers were synthesized over two-
steps. The presence of an alcohol functional group within Aba and 
NFV (C1 and C18) or DRV (C8) allowed us to introduce ester link-
ages to generate Aba-S2-NFV and Aba-S2-DRV analogs (Scheme 1). 
     In the first step of the synthesis of the heterodimers, Aba was 
treated with PyBOP-activated 4,4′-dithiodibutyric acid in the pres-
ence of DMAP and DIEA to produce Aba-S2-COOH (Scheme 1) in 
70% yield after purification by reverse phase HPLC (RP-HPLC). 
The selective acylation of the primary alcohol in Aba was established 
based on the resonances corresponding to the H-6 proton and the 
C-6 carbon of Aba-S2-COOH, that were shifted downfield from the 
corresponding proton H-6 and carbon C-6 signals in Aba by 0.7 ppm 
(4.1 ppm from 3.4 ppm) and 2.7 ppm (66.9 ppm from 64.2 ppm), 
respectively (Figure S3-S6).  
Acylation of NFV with Aba-S2-COOH was accomplished using 
the PI and Aba-S2-COOH in the presence of EDC/DMAP (Scheme 
1). NFV has two possible sites of acylation –C1 (phenolic) and C18 
(secondary hydroxyl) – that could potentially lead to 3 products: 
monoesters at C1 (Aba-S2-NFV1) and C18 (Aba-S2-NFV18), and a 
diester at both sites (Aba-S2)2-NFV (Scheme 1). Upon RP-HPLC 
separation, Aba-S2-NFV1 was isolated in 62% yield with < 5% of the 
other possible ester derivatives obtained. The structure of Aba-S2-
NFV1 was elucidated by 1H and 13C NMR spectroscopy, with peak 
assignments confirmed using COSY, TOCSY, HMQC and HMBC 
NMR (Figure S7-S16). The acylation of the phenolic alcohol of 
NFV in Aba-S2-NFV1 was confirmed by the observed deshielding of 
the protons H-2, H-3 and H-4, by 0.41 ppm, 0.22 ppm and 0.31 ppm, 
6 
a) 
b) 
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 respectively, as compared to the parent NFV (Figure S14). The for-
mation of the phenyl ester was further confirmed by 13C NMR, with 
shielding of the C-1 carbon signal by 6.4 ppm in Aba-S2-NFV1 as 
compared to NFV (Figure S15),37 and the deshielding of C-2, C-3 
and C-4 by 8-13 ppm (Figure S15). Furthermore, 1H and 13C reso-
nances in the vicinity of the secondary alcohol (H-10/C-10, H-
18/C-18 and H-19/C-19) showed no significant change in the spec-
tra of Aba-S2-NFV1 as compared to NFV (Figure S16). These NMR 
data taken together confirm the structure of Aba-S2-NFV1 as the 
phenyl ester derivative.  
The acylation of DRV was accomplished as described above 
(Scheme 1). DRV, like NFV, has two possible conjugation locations, 
the secondary alcohol on C8 (Aba-S2-DRV8) or the aniline N26, 
with the possible acylation at both sites ((Aba-S2)2-DRV). Upon RP-
HPLC separation of the reaction mixture, Aba-S2-DRV8 was ob-
tained in 27% yield with the diacylated product ((Aba-S2)2-DRV) in 
21% yield. The structure of Aba-S2-DRV8 was also elucidated by 1H 
and 13C NMR spectroscopy using COSY, TOCSY and HMQC 
NMR (Figure S17-S24). The acylation of the secondary alcohol of 
darunavir in Aba-S2-DRV8 was confirmed by the observed 
deshielding of the protons H-8 by 1.5 ppm, as compared to the par-
ent darunavir (Figure S22).  The formation of secondary ester was 
further confirmed by 13C NMR with the deshielding of the C-8 signal 
by 2.3 ppm in Aba-S2-DRV8 as compared to DRV (Figure S23).  
Furthermore, 1H and 13C NMR resonances in the vicinity of the ani-
line nitrogen (H-14/C-14 and H-15/C-15) showed no significant 
change in Aba-S2-DRV8 as compared to DRV (Figure S24).  These 
NMR data taken together confirmed that acylation proceeded on 
the secondary alcohol of darunavir. (Data for diacylated darunavir 
not shown). In all, this synthetic method allowed the preparation of 
two TH heterodimers, Aba-S2-NFV1 and Aba-S2-DRV8, for biolog-
ical analysis. 
2.3 Inhibition of P-gp efflux with Aba-S2-NFV1 and Aba-S2-DRV8. 
One of the goals of the designed TH heterodimers is to inhibit P-gp-
mediated efflux. A substrate accumulation assay was used to evaluate 
the potency of Aba-S2-NFV1 and Aba-S2-DRV8 as P-gp inhibitors 
using the P-gp substrates calcein-AM and NBD-Aba.38-39 Two cell 
lines were used to monitor the accumulation of these fluorescent P-
gp substrates: 12D7-MDR cells which are CD4+ T lymphocytes 
with overexpression of P-gp,40 and hCMEC/D3 cells as an in vitro 
BBB model cell line.41 hCMEC/D3 cells are an immortalized human 
brain capillary endothelial cell line that expresses endogenous levels 
of P-gp.42-43 Inhibition of P-gp efflux was measured by monitoring the 
increase in cellular fluorescence with added heterodimer by flow cy-
tometry. While the dimeric prodrugs have limited water solubility, 
they were fully soluble in 1% DMSO up to 100 µM, and, therefore, 
the cell-based P-gp experiments used 1% DMSO with no observed 
cytotoxicity. 
 With the 12D7-MDR and hCMEC/D3 cell lines, Aba-S2-NFV1 
and Aba-S2-DRV8 demonstrated dose-dependent, potent inhibition 
of P-gp efflux of calcein-AM and NBD-Aba with sub-micromolar 
IC50 values (Table 1). Aba-S2-DRV8 was the more potent of the two 
dimers with IC50 values of 80-90 nM in hCMEC/D3 cells. Interest-
ingly, the IC50 values obtained with the hCMEC/D3 cells are lower 
than 12D7-MDR cells, especially with Aba-S2-DRV8, likely due to 
the lower expression of P-gp in the brain capillary endothelial cells. 
Analogous experiments were performed with monomeric NFV and 
DRV using the fluorescent substrates. About a 3- to 12-fold increase 
in inhibition of P-gp was found with Aba-S2-NFV1 as compared to 
NFV, and a striking 66- to 118-fold increase in inhibition of P-gp was 
found for Aba-S2-DRV8 with respect to DRV alone (Table 1). Ab-
acavir has been shown to minimally inhibit (<10%) P-gp in 12D7-
MDR in cells up to 500 µM in these assays, whereas the known P-gp 
inhibitor verapamil had an IC50 value of 1.2 ± 0.4 µM in 12D7-MDR 
cells with the calcein-AM substrate .32 These data substantiate that 
the TH heterodimers are inhibitors of P-gp efflux in both T-cells and 
in a BBB cell model. Together, these IC50 data confirm that the di-
merization of two antivirals that are P-gp substrates – Aba and 
DRV/NFV – into one molecule successfully led to the generation of 
potent P-gp inhibitors. 
An MTT assay was used to determine the cell toxicity of Aba-S2-
NFV1 and Aba-S2-DRV8 in the 12D7-MDR cell lines after 24 
hours.44 In this assay, Aba-S2-NFV1 demonstrated high cell viability 
(>95%) at the maximum concentration used (20 µM). Aba-S-
DRV8, though slightly more cytotoxic than Aba-S2-NFV1, still main-
tained 70% cell viability at 20 µM, which is 40 times its IC50 for inhi-
bition of P-gp. These data suggest that the TH heterodimers are 
minimally cytotoxic to 12D7-MDR cells at bioactive concentrations 
and can be used for further biological assays without detrimental ef-
fect on cell growth. 
2.4 Probing the reversion of TH heterodimers into monomers in a 
reducing environment. In a reducing environment the disulfide 
bonds within the TH heterodimers would yield 2 thiols (Figure 1a) 
that may rearrange to produce monomeric drugs (Aba, NFV and 
DRV). The breakdown of the TH heterodimers with DTT and glu-
tathione (GSH), and the release of monomers was monitored using 
UPLC-MS at various timepoints. The reduction of the heterodimers 
to free thiols occurs rapidly, with full reduction observed within 1 
hour. Upon appearance of free thiols, the subsequent rearrangement 
Table 1. Inhibition of P-gp mediated efflux of calcein-AM and NBD-Aba in 12D7-MDR and hCMEC/D3 cellsa 
 IC50 (µM) 
 12D7-MDR cells hCMEC/D3 cells 
Compound calcein-AM NBD-Aba calcein-AM NBD-Aba 
NFV 9.1 ± 3.0 5.8 ± 1.4 2.0 ± 0.2 1.7 ± 0.3 
Aba-S2-NFV1 0.77 ± 0.05 0.65 ± 0.09 0.59 ± 0.07 0.41 ± 0.06 
DRV 33.2 ± 6.5 60 ± 9.4 6.6 ± 1.9 15.4 ± 3.2 
Aba-S2-DRV8 0.50 ± 0.04 0.51 ± 0.08 0.08 ± 0.02 0.09 ± 0.02 
a Cells were treated with calcein-AM (0.25 µM) or NBD-Aba (5 µM) with different concentrations of compound. The accumulated fluorescence was analyzed 
using flow cytometery.  
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 led to the generation of the component monomeric drugs. Aba re-
generation from each TH heterodimer (Aba-S2-NFV1 and Aba-S2-
DRV8) was consistent between heterodimers with a half-life (t1/2) of 
31.8 ± 6.8 and 34.5 ± 1.5 hours, respectively with DTT, and 29.4 ± 3 
and 21.6 ± 2 hours, respectively with with GSH. DRV and NFV were 
regenerated with a t1/2 of 21.3 ± 0.8 and 1.2 ± 0.2 hours with DTT, 
respectively, and 36.3 ± 4 and 10.3 ± 1 hours with GSH. Interest-
ingly, NFV was released significantly faster than the release of DRV 
and Aba. This significant difference in monomer release is likely due 
to the differences in the chemical connectivity of the monomers. 
NFV, as described above, is connected to the tether via a phenolic 
moiety, whereas DRV is linked by a secondary alcohol. The better 
leaving group ability of the phenol versus the secondary alcohol 
likely leads to the observed difference in monomer regeneration.  
2.5 The anti-HIV-1 potency of each TH heterodimer as compared 
to their monomers, alone and combined. To investigate if Aba-S2-
NFV1 and Aba-S2-DRV8 are effective against HIV-1 in cells, an in 
vitro HIV-1 titer assay was performed using the 12D7 cell line. 12D7 
cells were infected with HIV-1LAI  and anti-HIV-1 activity was meas-
ured by monitoring p24 protein levels as previously described.45-46 
First the stability of the prodrugs was monitored in PBS and cell cul-
ture media using UPLC-MS. Aba-S2-NFV1 was greater than 95% in-
tact after 1 week under both condition, whereas Aba-S2-DRV8 was 
also greater than 95% intact after 3 days under both conditions, but 
with decomposition observed after day 4. Therefore, for the cell-
based anti-HIV-1 experiments, the media, with drugs, was changed 
every 3 days. The anti-HIV-1 activity of different concentrations of 
monomeric drugs alone (Aba, NFV or DRV), 1:1 combinations of 
an RTI with a PI (Aba and NFV or Aba and DRV) or the TH heter-
odimer was determined after 6 days. All drugs and drug combina-
tions demonstrated a decrease in p24 levels as compared to the con-
trol, which corresponds to an increase in anti-HIV-1 activity. The 
PIs used are known to be superior antivirals as compared to the RTI 
Aba,47 and this was also observed (Figure 2). Therefore, the an-
tiretroviral activity of the 1:1 mix of Aba with NFV or DRV was dom-
inated by the PI potency. For the TH heterodimers, the anti-HIV-1 
activity of Aba-S2-NFV was similar to the 1:1 mixture of Aba and 
NFV, whereas Aba-S2-DRV was less potent than the 1:1 mixture of 
Aba and DRV. DRV alone is a highly potent antiviral and is more 
potent than NFV alone48 (Figure 2). Therefore, one might expect 
that Aba-S2-DRV8 would have superior anti-HIV-1activity as com-
pared to Aba-S2-NFV1.  However, the release of NFV from Aba-S2-
NFV1 is 18-fold faster than DRV release from Aba-S2-DRV8 due to 
the better phenolic leaving group. Thus, this difference in chemical 
connectivity leads to a difference in monomer release, that may be 
responsible for the differences in anti-HIV-1 potency. 
3. Conclusion 
Herein, the successful synthesis and application of two TH hetero-
dimers, Aba-S2-NFV1 and Aba-S2-DRV8, as P-gp inhibitors and an-
tiviral prodrugs is discussed. Each heterodimer was synthesized and 
the connectivity points within the monomers was fully characterized 
by NMR. Both TH heterodimers are potent P-gp inhibitors with ac-
tivity in T-cells and endothelial cells from the BBB. These dimers 
were found to revert to their component monomers (Aba, NFV and 
DRV) in a reducing environment, with NFV releasing significantly 
faster than DRV. Both TH heterodimers displayed anti-HIV-1 activ-
ity in T cells, with Aba-S2-NFV1 displaying superior potency as com-
pared to Aba-S2-DRV8. The quicker regeneration of monomeric 
NFV in the reducing environment and, in turn, the superior anti-
HIV potency of Aba-S2-NFV1 as compared to Aba-S2-DRV8, is 
likely due to the better phenolic leaving group in Aba-S2-NFV. Thus, 
chemical connectivity to the tether within these TH heterodimers 
has a notable effect on the observed anti-HIV-1 activity. Future stud-
ies may probe alternate linking chemistry to promote more facile re-
lease of the combination therapies from the TH prodrugs.  
4. Experimental 
4.1 Materials.  Abacavir, darunavir and nelfinavir were provided by 
the NIH AIDS Reagent Program (Germantown, MD). ((1H-
benzo[d][1,2,3]triazol-1-yl)oxy)tri(pyrrolidin-1-yl)phosphonium 
hexafluorophosphate (PyBOP) was bought from GenScript Corpo-
ration (Piscataway, NJ). DTT was purchased from Roche (Indian-
apolis, IN). 1-(3-Dimethylaminoproyl)-3-ethylcarbodiimide hydro-
chloride (EDC) was purchased fom AK Scientific (Union City, CA). 
4,4′-Dithiodibutyric acid,N,N-dimethylpyridin-4-amine (DMAP) 
and N-ethyl-N-isopropylpropan-2-amine (DIEA) were purchased 
from Sigma-Aldrich (St. Louis, MO). hCMEC/D3 cells were 
donated from Institut National de la Sante et de la Recherche Med-
icale (INSERM, Paris, France). Rat tail collagen I was purchased 
from BD Biosciences (San Jose, CA). EBM-2 growth medium was 
purchased from Lonza (Basel, Switzerland). Calcein-AM was 
bought from Invitrogen (Carlsbad, CA), All other reagents were 
either purchased from Sigma Aldrich (St. Louis, MO). or Invitrogen 
(Carlsbad, CA) and used without further purification.1H, 13C, and 
2D NMR spectra were recorded with a Bruker AC 800 and Bruker 
AC 500 MHz. DMSO-d6 was used to prepare NMR samples. 
4.2 Methods 
S y n t h e s i s  o f  A b a - S 2 - C O O H  
To a solution of 4,4′-dithiodibutyric acid (400 mg, 1.7 mmol) was 
added PyBOP (114 mg, 0.22 mmol), DIEA (0.20 ml, 0.75 mmol) 
and DMAP (2.6 mg, 0.022 mmol) under nitrogen atmosphere at 
room temperature in dry DMF (2 ml). After 20 min, abacavir sulfate 
  
Figure 2. Anti-HIV-1 activity of individual RTI or PI antivirals, 
a 1:1 mixture of RTI and PI, and the TH heterodimers in HIV-
1LAI infected 12D7 cells. The plotted data is the average of HIV-
1 p24 with the standard deviation derived from two independ-
ent experiments.  
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 (50 mg, 0.15 mmol) was added. The mixture was left to stir at room 
temperature for 24 hours. The resulting reaction mixture was dis-
solved in DMSO and purified using RP-HPLC. The RP-HPLC sol-
vent consisted of acetonitrile with 0.1 % TFA (solvent A) and water 
with 0.1 % TFA (solvent B). A gradient of 20–70% of solvent A with 
the flow rate of 12.0 mL/min and UV detection at 214 nm and 280 
nm with a C8 column (Phenomenex, USA) was used for purifica-
tion. Purity of the product (~99%) was estimated by C8 analytical 
RP-HPLC using a flow rate of 1.2 mL/min and UV detection at 214 
and 280 nm and a gradient from 20-70% (solvent A) over 30 mins. 
The retention time for Aba-S2-COOH was found to be 16.2 mins. 
The yield for this reaction was calculated to be 70%. Calculated mass 
for Aba-S2-COOH 506.18, observed mass by ESI-MS 507.2 
[M+H]+. 
Aba-S2-COOH: 1H NMR (500 MHz, DMSO-d6) δ 12.18 (s, 2H), 
9.77 (s, 1H), 7.93 (s, 1H), 7.45 (s, 2H), 6.13 (dd, J = 5.3, 2.5 Hz, 
1H), 5.98 (dt, J = 5.1, 2.2 Hz, 1H), 5.43 (ddd, J = 8.6, 6.1, 2.4 Hz, 
1H), 4.09 (d, J = 6.1 Hz, 2H), 3.11 (ddt, J = 12.0, 8.5, 4.1 Hz, 1H), 
2.85 (s, 1H), 2.68 (qd, J = 8.1, 7.2, 4.4 Hz, 5H), 2.38 (td, J = 7.3, 4.4 
Hz, 2H), 2.29 (t, J = 7.2 Hz, 2H), 1.82 (dp, J = 11.4, 7.2 Hz, 4H), 
1.62 (dt, J = 13.8, 5.9 Hz, 1H), 0.88 (s, 2H), 0.74 (s, 2H); 13C NMR 
(126 MHz, DMSO-d6) δ 174.34, 172.85, 159.09, 158.84, 158.59, 
137.79, 130.49, 118.60, 116.23, 66.72, 59.61, 45.70, 44.48, 40.48, 
40.32, 40.15, 39.98, 39.82, 39.65, 39.48, 37.28, 37.10, 34.71, 32.54, 
32.34, 26.07, 24.43, 24.40, 7.39. 
S y n t h e s i s  o f  A b a - S 2 - N F V 1  
To a flame dried round bottom flask under nitrogen, was added 
NFV (20 mg, 34.8 µmol), Aba-S2-COOH (21.5 mg, 34.8 µmol), 
EDC (10 mg, 52.2 µmol), DMAP (8.5 mg, 69.7 µmol), DIEA (60µl, 
348 µmol) and 4 Å powdered molecular sieves followed by dry 
DCM (1 ml) at 0 °C. The reaction mixture was stirred at room tem-
perature for 24 hours, and the progress of the reaction was moni-
tored by RP-HPLC. An additional aliquot of EDC (10 mg, 52.2 
µmol) was added after 24 hours and the reaction mixture was stirred 
for an additional 2 days. The mixture was diluted with DMSO and 
components separated by RP-HPLC on a C18 column (Phenom-
enex, USA) with a flow rate of 12 ml/min, a gradient of 20–60% sol-
vent A over 60 min and UV detection at 214 nm and 254 nm. Aba-
S2-NFV1 was obtained (62% yield, major product) with Aba-S2-
NFV18 and (Aba-S2)2-NFV (5% yield, minor products). Aba-S2-
NFV1 (major product) had a purity of 99% by RP-HPLC (Figure 
S2), and the compound was fully characterized by NMR (see below 
and Figures S7-16). ESI-MS: calculated mass: 1056.5, observed 
mass: 1057.0; high resolution MS: calculated mass: 1056.4868, ob-
served mass: 1056.4890.  
Aba-S2-NFV1: 1H NMR (800 MHz, DMSO-d6) δ 9.85 (s, 1H), 9.20 
(s, 1H), 8.37 (d, J = 8.9 Hz, 1H), 8.21 (s, 1H), 7.97 (s, 1H), 7.63 (s, 
2H), 7.38 – 7.29 (m, 5H), 7.28 (t, J = 7.8 Hz, 1H), 7.23 – 7.19 (m, 
1H), 7.16 (dt, J = 8.0, 1.9 Hz, 1H), 6.14 (dt, J = 5.7, 2.1 Hz, 1H), 5.98 
(dt, J = 5.7, 2.2 Hz, 1H), 5.43 (ddd, J = 10.7, 4.8, 2.0 Hz, 1H), 4.14 – 
4.05 (m, 3H), 3.94 (q, J = 10.5 Hz, 1H), 3.87 (s, 1H), 3.56 (d, J = 
12.9 Hz, 1H), 3.41 (dd, J = 13.7, 2.9 Hz, 1H), 3.28 (s, 1H), 3.23 (d, 
J = 13.4 Hz, 1H), 3.10 (ddq, J = 8.3, 6.3, 2.1 Hz, 1H), 3.03 – 2.98 (m, 
2H), 2.84  – 2.67 (m, 8H), 2.45 – 2.34 (m, 2H), 2.16 (d, J = 3.8 Hz, 
3H), 2.08 – 1.98 (m, 2H), 1.96 – 1.90 (m, 3H), 1.86 (dp, J = 21.4, 
7.2 Hz, 2H), 1.76 (m, 1H), 1.71 (d, J = 12.7 Hz, 2H), 1.63 (dt, J = 
13.9, 5.9 Hz, 1H), 1.54 (t, J = 6.3 Hz, 2H), 1.40 (d, J = 12.4 Hz, 1H), 
1.36 – 1.32 (m, 1H), 1.29– 1.15 (m, 11H), 0.92 – 0.88 (m, 2H), 0.78 
(s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 172.85, 171.51, 169.09, 
167.53, 158.91, 158.63, 152.99, 149.67, 139.23, 137.89, 136.34, 
130.38, 129.55, 128.93, 128.21, 126.71, 126.44, 125.41, 123.90, 
112.11, 68.91, 67.15, 66.72, 59.74, 58.96, 57.91, 52.60, 51.43, 44.48, 
36.99, 34.68, 34.13, 33.99, 32.33, 32.25, 31.72, 30.21, 29.48, 28.84, 
28.62, 25.99, 25.04, 24.37, 24.31, 23.61, 20.40, 13.32, 7.41. 
Synthesis of Aba-S2-DRV8 
To a flame dried round bottom flask under nitrogen, was added 
DRV (20 mg, 36µmol), Aba-S2-COOH (21.5 mg, 34.8 µmol), EDC 
(10 mg, 52.2 µmol), DMAP (8.5 mg, 69.7 µmol), DIEA (60µl, 348 
µmol) and 4 Å powdered molecular sieves followed by dry DCM (1 
ml) at 0 °C. The reaction mixture was stirred at room temperature 
for 72 hours, and the progress of the reaction was monitored by RP-
HPLC. The reaction mixture was diluted with DMSO and compo-
nents separated by RP-HPLC on a C18 column (Phenomenex, 
USA) with a flow rate of 12 ml/min, a gradient of 20–95% solvent A 
over 60 min and UV detection at 214 nm and 254 nm. Aba-S2-DRV 
was obtained (27% yield, major product) with (Aba-S2)2-DRV (21% 
yield, minor product). The retention time of Aba-S2-DRV8 (major 
product) had a purity of 99% (Figure S1), and the compound was 
fully characterized by NMR (see below and Figures S17-S24). ESI-
MS: calculated mass: 1036.4, observed mass: 1036.8; high resolu-
tion MS: calculated mass: 1036.4089, observed mass: 1036.4106.  
Aba-S2-DRV8: 1H NMR (800 MHz, DMSO-d6) δ 7.48 (d, J = 9.4 
Hz, 1H), 7.39 (d, J = 8.7 Hz, 1H), 7.21 (dt, J = 15.3, 7.1 Hz, 3H), 
7.16 – 7.13 (m, 1H), 6.61 (d, J = 8.7 Hz, 1H), 6.12 (dt, J = 5.6, 2.1 
Hz, 1H), 5.96 (dt, J = 5.6, 2.2 Hz, 1H), 5.48 (d, J = 5.2 Hz, 1H), 5.41 
(ddq, J = 8.2, 6.2, 2.1 Hz, 1H), 5.06 (ddd, J = 9.0, 4.5, 2.8 Hz, 1H), 
4.84 (dt, J = 8.0, 5.8 Hz, 1H), 4.07 (dd, J = 6.2, 2.1 Hz, 2H), 3.95 
(ddd, J = 14.9, 9.1, 4.1 Hz, 1H), 3.85 (dd, J = 9.6, 6.0 Hz, 1H), 3.69 
(td, J = 8.2, 1.9 Hz, 1H), 3.56 (ddt, J = 16.4, 8.3, 5.6 Hz, 2H), 3.29 
(dd, J = 15.4, 2.9 Hz, 1H), 3.08 (ddp, J = 8.3, 6.2, 2.0 Hz, 1H), 3.04 
(dd, J = 15.3, 9.0 Hz, 1H), 2.81 (dt, J = 13.4, 3.8 Hz, 2H), 2.78 – 2.72 
(m, 1H), 2.69 (dt, J = 18.8, 7.1 Hz, 4H), 2.60 – 2.51 (m, 1H), 2.50 – 
2.47 (m, 3H), 2.42 – 2.38 (m, 1H), 2.38 – 2.30 (m, 3H), 2.06 (s, 
0H), 1.91 – 1.85 (m, 2H), 1.83 (q, J = 7.3 Hz, 2H), 1.78 (ddt, J = 
13.1, 9.0, 6.5 Hz, 1H), 1.61 (dt, J = 13.8, 5.9 Hz, 1H), 1.39 – 1.30 (m, 
1H), 1.17 – 1.11 (m, 1H), 0.77 (dd, J = 6.6, 4.5 Hz, 5H). 13C NMR 
(800 MHz, DMSO-d6) δ 172.82, 172.35, 155.81, 153.44, 138.77, 
137.77, 130.46, 129.56, 129.52, 128.48, 126.54, 123.29, 113.18, 
109.22, 109.20, 75.08, 73.07, 70.65, 69.25, 66.72, 59.60, 57.73, 
53.72, 49.50, 45.47, 44.45, 40.29, 40.18, 40.08, 39.97, 39.87, 39.77, 
39.66, 37.08, 37.05, 35.56, 34.68, 32.51, 32.30, 26.82, 25.89, 24.34, 
24.07, 23.56, 20.37, 20.21. 
C e l l  C u l t u r e   
12D7-MDR cells were grown in complete RPMI 1640 media 
with vincristine (0.5 ng/mL), 50 units/mL of penicillin and 
50μg/mL streptomycin, 5 mM of L-glutamine and 10 % FBS. The 
growth of cells was maintained at 37 o C in 5% CO2. hCMEC/D3 
cells were cultured according to literature protocols with minor 
modifications.41  The media used for growth consisted of endothelial 
growth medium-2 (EGM-2) supplemented with 5% fetal bovine se-
rum, 1 % penicillin-streptomycin, 0.5% human basic fibroblast 
growth factor (hbFGF), 1.4 µM hydrocortisone, 5 µg/mL ascorbic 
acid, 1% (10 mM) HEPES and 1% lipid concentrate.  
F l o w  C y t o m e t r y  A s s a y   
Flow cytometry was used to estimate P-gp inhibition using a sub-
strate accumulation assay as described previously with some minor 
changes.38 BME media (with fluorescent P-gp substrate) along with 
the compound of interest in DMSO (1%) was added to 125,000 cells 
in suspension and stored in a CO2 incubator at 37 °C for 30 mins. 
The cells were harvested by centrifugation at 300 x g at 4 °C for 7 
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 mins. The supernatant was carefully removed, and 400 µl of cold, 
sterile PBS was added to the cell pellet. The accumulation of calcein-
AM or NBD-Aba was measured using a FACSCalibur flow cytome-
ter (BD Biosciences) with an excitation wavelength of 488 nm argon 
laser and an emission 530 nm bandpass filter (FL1). The mean fluo-
rescence value for each concentration corresponded to 10,000 cells. 
Each sample was run in duplicate and all the experiments were run 
in duplicates on two different days. The average fluorescence accu-
mulated in the cells for samples was used to plot the mean fluores-
cence vs. concentration, and the IC50 values were estimated using the 
Graph Pad Prism.  
C e l l  V i a b i l i t y  A s s a y   
The viability of 12D7-MDR cells in the presence of a TH hetero-
dimer (Aba-S2-NFV1 or Aba-S2-DRV8) was measured using the 
standard MTT assay.44 20,000 12D7-MDR cells were plated in 96-
well plate in 100 μL of cell media. After 12 hours, TH heterodimer 
in media was added to each well to give a final concentration of 5, 10 
and 20 µM (1% DMSO). After 24 hours 20 µl of MTT in PBS (5 
mg/mL) was added to all the wells and incubated for 2.5 hours. The 
96 well plates were centrifuged at 300 x g for 7 mins, followed by 
careful removal of supernatant. 100 µl of DMSO was added to dis-
solve the formazan. The absorbance of the DMSO solution was read 
using plate reader at 590 nm. Cell viability was reported as the ratio 
of absorbance of cells treated with TH heterodimer relative to cells 
treated with DMSO. 
S t a b i l i t y  o f  T H  h e t e r o d i m e r s  w i t h  D T T  
Stability studies with DTT and GSH were adapted from a previ-
ously published protocol with some changes.32 Aba-S2-NFV1 and 
Aba-S2-DRV8 (4 μM) were incubated at 37 °C with 250 mM DTT 
or 10 mM GSH in degassed 30% methanol/ PBS (pH ~7.4) contain-
ing 5 µM quinine as the internal standard. When monitoring NFV 
and DRV release, an aliquot of the reaction mixture was taken at dif-
ferent time points and directly analyzed by UPLC-MS. For analysis 
of Aba release, an aliquot of reaction mixture was taken and stored at 
-80 °C before analysis. The time points were analyzed using RP-
UPLC with a C18 column consisting of solvent A (water and 0.1% 
formic acid) and solvent B (acetonitrile and 0.1% formic acid), a gra-
dient of 5-95% of solvent B over 10 mins and a flow rate of 0.5 
ml/min. The peaks corresponding to m/z for quinine (325.4), Aba-
S2-NFV1 (1056.4), Aba-S2-DRV8 (1036.5), Aba-SH (389.4), Aba 
(287.4), NFV (568.6) and DRV (548.4) were detected and ex-
tracted using MassLynx software. The experiments were run in du-
plicate, and the average percentage of release vs time was fitted using 
Graph Pad Prism 7 to generate t1/2’s. 
S t a b i l i t y  o f  A b a - S 2 - N F V 1  a n d  A b a - S 2 - D R V 8  i n  c e l l  
c u l t u r e  m e d i a  
The cell media stability studies for the TH heterodimers (Aba-
S2-NFV1 or Aba-S2-DRV8) was carried out following a previously 
published protocol with some modifications.32 Heterodimers (100 
µM) were incubated at 37 °C in the cell media used for 12D7 cells 
(complete RPMI 1640 media with 50 units/mL of penicillin and 
50μg/mL streptomycin, 5 mM of L-glutamine and 10 % FBS) with 
1% DMSO. Every 24 hours ice-cold acetonitrile with 4-methoxyben-
zyl alcohol (1.0 mM) was added to an aliquot of the reaction mixture 
(1:1). The resultant solution was vortexed for 1 min, sonicated for 
10 mins and centrifuged twice at 10000 x g for 10 mins each. The 
supernatant was stored at -80 °C. All samples were analyzed using a 
C8 analytical column (Phenomenex, USA) on RP-HPLC with elu-
ent consisting of solvent A (water and 0.05% TFA) and solvent B 
(acetonitrile and 0.05% TFA). A gradient of 15-75% solvent B over 
30 min with a flow rate of 1.2 ml/min and UV detection at 254 nm 
was used. The assays were performed in duplicate.  
H I V - 1  c e l l  i n h i b i t i o n  a s s a y  
 12D7 cells were grown in the identical media for the cell culture me-
dia stability studies. The cells in log-phase were pelleted and resus-
pended at 1 million cells per ml. 500 TCID50 HIV-1LAI was used to 
infect cells for 4 hours using a known procedure.45 These infected 
cells were plated at a density of 75,000 cells per ml in 48-well plates 
after three washes with the media. Different concentrations of the 
compound of interest were added keeping the DMSO concentration 
at 0.05%. After three days, the media was replaced with fresh media 
containing the same concentration of the compound of interest. On 
the 6th day, the supernatant was analyzed using ELISA to quantify 
the amount of HIV-1 p24 (gag) protein generated in each sample.46 
All assays were run in duplicate.  
ASSOCIATED CONTENT  
Supporting Information. Materials include: Analytical RP-HPLC traces 
of both TH heterodimers (Aba-S2-NFV1 and Aba-S2-DRV8). The 1H, 
13C, COSY, TOCSY, HMBC, and HMQC NMR spectra for Aba-S2-
NFV1, with 1H and 13C comparison to NFV. The 1H, 13C, COSY, 
TOCSY, and HMQC NMR spectra for Aba-S2-DRV8, with 1H and 13C 
comparison to DRV, and SMILES.  This material is available free of 
charge via the Internet at http://pubs.acs.org. 
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 SYNOPSIS TOC 
Heterodimers of HIV protease and reverse transcriptase inhibitors linked via a traceless tether are potent inhibitors of cellular P-gp efflux, 
and, in a reducing environment, revert to a monomeric combination therapy with in cyto anti-HIV-1 activity. 
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